psilocybin therapy

Mental health care company COMPASS Pathways plc (NASDAQ: CMPS) has announced positive data demonstrating the potential of its proprietary synthetic psilocybin compound COMP360 in treating depression within Type II bipolar disorder. Presented at the American College of Neuropsychopharmacology...

The ongoing battle led by palliative care specialist Dr. Sunil Aggarwal to pressure the DEA to allow end-of-life treatments for patients seeking to use psychedelics introduced another chapter.  The agency replied to Dr. Aggarwal’s petition last month stating that...

Educational platform training and certifying psychedelic therapists Fluence has been selected by Oregon’s Higher Education Coordinating Commission (HECC) and the Oregon Health Authority (OHA) to be a state-licensed provider of training for licensed facilitators to provide psilocybin services...

A recent study published by life sciences company Grace Health & Wellness aims to raise awareness on the possibility of using medical cannabis and psychedelics to propel traditional pharmaceuticals. The study presented positive outcomes in a case of advanced breast cancer,...

(Part three of a four-part series) Despite ongoing legal setbacks, psychedelics research has reemerged and it is proving that psilocybin reduces brain connections within the usual networks while amplifying links between less connected areas.  Alterations on sustained networks seem to...

(Part one of a four-part series) In recent years, evidence supporting the use of psychedelics for the treatment of unmet mental health disorders such as PTSD, depression, addictions and anxiety has done nothing but grow. Let’s dive into one of the substances emerging as potentially more...

Life sciences company Revive Therapeutics Ltd. (OTCQB: RVVTF) is advancing its first Phase I/II clinical trial of oral psilocybin for methamphetamine use disorder treatment while also developing an oral psilocybin thin film strip product. Revive is currently studying psilocybin’s potential as...

Biotech drug discovery firm Mindset Pharma Inc. (OTCQB: MSSTF) develops next-generation psychedelic and non-psychedelic medicines for neuropsychiatric and neurological disorders. To pursue their goal it received scientific advice from the UK Medicines and Healthcare Products Regulatory Agency...

Two psychedelics companies have announced they’ll be collaborating to offer ketamine infusions in the US and psilocybin clinical retreats internationally with a special focus on  access needs for veterans.  The present agreement was signed between Revitalist Lifestyle and...

Cathie Wood’s ARK Genomic Revolution EFT has been making big investments in the psychedelics sector since February 2022, most notably in Atai Life Sciences (NASDAQ: ATAI). The fund has now gone deeper and released an extensive report exploring “the therapeutic merits”...

This article was originally published on Psychedelic Spotlight and appears here with permission. A year after a Johns Hopkins psilocybin-assisted therapy study, researchers find even more stunning results, showing the power of two doses. While there have been many studies showing that psilocybin-...

This article was originally published on The Bluntness and appears here with permission. Depression is one of the most widespread and difficult to treat mental illnesses on the planet.  But finally, help is coming from a fungi with brain-friendly psychoactive properties – the so-called...

atai Life Sciences (NASDAQ: ATAI) on Thursday announced Invyxis, a new program to accelerate the company’s portfolio of compounds. What Happened: The clinical-stage biotechnology company focused on discovering and developing mental health treatments using psychedelic therapy said...

Psilocybin-focused mental health care company COMPASS Pathways plc (NASDAQ: CMPS) announced Monday it had achieved positive results from its exploratory study of COMP360 psilocybin therapy in conjunction with SSRI use. SSRI, or selective serotonin reuptake inhibitors, are the most commonly...

Biopharmaceutical conglomerate ATAI Life Sciences (NASDAQ: ATAI), a Peter Thiel-backed psychedelic startup that currently has 10 psychedelic programs in the works, has upped its stake in Compass Pathways (NASDAQ: CMPS), a drug developer looking to accelerate patient access to psilocybin...